Company Encyclopedia
View More
name
Milestone Pharmaceuticals
MIST.US
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
4.514 T
MIST.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | MIST Stock News

    Milestone Pharmaceuticals announced the granting of 30,000 options to purchase common shares as part of its 2021 Inducement Plan, approved by the Compensation Committee and Board of Directors. These options, with an exercise price of $2.69 per share, are intended as an inducement for hiring two new employees, in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with specific vesting conditions.

    StockTitan·
    US
    MIST
    +0.76%
    StockTitan·
    US
    MIST
    +0.76%

    Wells Fargo Sticks to Its Buy Rating for Milestone Pharmaceuticals (MIST)

    Wells Fargo analyst Mohit Bansal maintained a Buy rating on Milestone Pharmaceuticals with a $4.00 price target. Bansal, a 4-star analyst with a 9.4% average return, covers the Healthcare sector. H.C. Wainwright also reiterated a Buy rating with a $5.00 price target.

    Tip Ranks·
    US
    MIST
    +0.76%
    Tip Ranks·
    US
    MIST
    +0.76%

    Milestone Pharmaceuticals Reports Q3 2025 Financial Results

    Milestone Pharmaceuticals Reports Q3 2025 Financial Results

    Tip Ranks·
    US
    MIST
    +0.76%
    Tip Ranks·
    US
    MIST
    +0.76%

    Milestone Pharmaceuticals: Positioned for Success with Cardamyst’s Potential Approval and Launch

    Analyst Brandon Folkes from H.C. Wainwright maintains a Buy rating on Milestone Pharmaceuticals with a price target of $5.00, driven by the potential approval of Cardamyst, a nasal spray for PSVT, expected in December 2025. The product is positioned as a first-to-market therapy that could enhance patient care. Milestone has improved its financial standing and resolved prior regulatory issues, leading to FDA acceptance of their NDA. This positions the company for significant stock performance, especially with the promising AFib-RVR program.

    Tip Ranks·
    US
    MIST
    +0.76%
    Tip Ranks·
    US
    MIST
    +0.76%

    Milestone Pharmaceuticals | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    MIST
    +0.76%
    LB filings·
    US
    MIST
    +0.76%
    Posts
    View More
    © 2025 Longbridge｜Disclaimer